Drugs for Hypoplastic Left Heart Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 43)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ambrisentan |
Approved, Investigational |
Phase 2 |
|
177036-94-1 |
6918493 |
Synonyms:
(2S)-2-[(4,6-DIMETHYLPYRIMIDIN-2-YL)OXY]-3-METHOXY- 3,3-DIPHENYLPROPANOIC ACID
AMBRISENTAN
GSK1325760
GSK-1325760
GSK1325760A
|
GSK-1325760A
LETAIRIS
Letairis®
LU-208075
VOLIBRIS
|
|
2 |
|
Sodium citrate |
Approved, Investigational |
Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
3 |
|
Sildenafil |
Approved, Investigational |
Phase 2 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
4 |
|
Bosentan |
Approved, Investigational |
Phase 2 |
|
147536-97-8 |
104865 |
Synonyms:
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulphornamide
4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
BOSENTAN
BOSENTÁN
Bosentan anhydrous
Bosentan hydrate
Bosentan monohydrate
|
Bosentanum
p-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulphonamide
RO 47-0203
RO 47-0203|Tracleer®
RO-470203029
RO-47-0203-029
Tracleer
|
|
5 |
|
Oxandrolone |
Approved, Investigational |
Phase 1, Phase 2 |
|
53-39-4 |
5878 |
Synonyms:
Anavar
NSC-67068
Ossandrolone
Oxandrin
Oxandrolon
Oxandrolona
|
Oxandrolone
OXANDROLONE CIII
Oxandrolonum
PROTIVAR
SC-11585
|
|
6 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 2 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
7 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
8 |
|
Kava |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
9000-38-8 |
|
9 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
10 |
|
Epoetin Alfa |
|
Phase 1, Phase 2 |
|
|
|
Synonyms:
BINOCRIT
EPO
EPOETIN ALFA
EPOGEN
|
EPREX
ERYTHROPOIETIN PRECURSOR
PROCRIT
|
|
11 |
|
Hematinics |
|
Phase 1, Phase 2 |
|
|
|
12 |
|
Phosphodiesterase Inhibitors |
|
Phase 2 |
|
|
|
13 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 2 |
|
|
|
14 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
15 |
|
Citrate |
|
Phase 2 |
|
|
|
16 |
|
Endothelin Receptor Antagonists |
|
Phase 2 |
|
|
|
17 |
|
Anabolic Agents |
|
Phase 1, Phase 2 |
|
|
|
18 |
|
Hormones |
|
Phase 1, Phase 2 |
|
|
|
19 |
|
Hormone Antagonists |
|
Phase 1, Phase 2 |
|
|
|
20 |
|
Androgens |
|
Phase 1, Phase 2 |
|
|
|
21 |
|
Epinephryl borate |
|
Phase 2 |
|
|
|
22 |
|
Dexmedetomidine |
Approved, Experimental, Vet_approved |
Phase 1 |
|
86347-14-0, 113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
(+-)-4-(a,2,3-Trimethylbenzyl)imidazole
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole
(+-)-4-(Α,2,3-trimethylbenzyl)imidazole
(+)-MEDETOMIDINE
(±)-4-(α,2,3-trimethylbenzyl)imidazole
(S)-MEDETOMIDINE
Dexdor
Dexdor®|Igalmi® (dexmedetomidine sublingual film)|MPV 1440|Precedex®
DEXMEDETOMIDIN
Dexmedetomidina
DEXMEDETOMIDINE
DEXMÉDÉTOMIDINE
Dexmedetomidine hydrochloride
Dexmedetomidinum
|
Domitor
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Hydrochloride, medetomidine
Levomedetomidine
Medetomidina
Medetomidina [Spanish]
Medetomidine
Medetomidine hydrochloride
Medetomidinum
Medetomidinum [Latin]
MPV 1440
MPV 785
MPV-1440
MPV-785
Precedex
|
|
23 |
|
Poractant alfa |
Approved |
Phase 1 |
|
129069-19-8 |
|
24 |
|
Adrenergic alpha-Agonists |
|
Phase 1 |
|
|
|
25 |
|
Adrenergic Agonists |
|
Phase 1 |
|
|
|
26 |
|
Adrenergic Agents |
|
Phase 1 |
|
|
|
27 |
|
Neurotransmitter Agents |
|
Phase 1 |
|
|
|
28 |
|
Hypnotics and Sedatives |
|
Phase 1 |
|
|
|
29 |
|
Analgesics, Non-Narcotic |
|
Phase 1 |
|
|
|
30 |
|
Analgesics |
|
Phase 1 |
|
|
|
31 |
|
Pulmonary Surfactants |
|
Phase 1 |
|
|
|
32 |
|
Respiratory System Agents |
|
Phase 1 |
|
|
|
33 |
|
Benzocaine |
Approved, Investigational |
|
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
34 |
|
Tannic acid |
Approved |
|
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
35 |
|
Ascorbic acid |
Approved, Nutraceutical |
|
|
50-81-7 |
54676860 54670067 5785 |
Synonyms:
(+)-Ascorbate
(+)-Ascorbic acid
(+)-Sodium L-ascorbate
[<sup>14</sup>C]-ascorbic acid
3-keto-L-Gulofuranolactone
3-oxo-L-Gulofuranolactone
AA
Acid, ascorbic
Acid, L-ascorbic
Acide ascorbique
Acido ascorbico
ácido ascórbico
Acidum ascorbicum
Acidum ascorbinicum
Adenex
Allercorb
Antiscorbic vitamin
Antiscorbutic vitamin
arco-Cee
Ascoltin
ASCOR
Ascorb
Ascor-b.i.d.
Ascorbajen
Ascorbate
Ascorbate radical
Ascorbate, ferrous
Ascorbate, magnesium
Ascorbate, sodium
ASCORBIC ACID
Ascorbic acid radical
Ascorbic acid, monosodium salt
Ascorbicab
Ascorbicap
Ascorbicin
Ascorbin
Ascorbinsaeure
Ascorbinsäure
Ascorbutina
Ascorin
Ascorteal
Ascorvit
Cantan
Cantaxin
Catavin C
Ce lent
Cebicure
Cebid
Cebion
Cebione
Cecon
Cee-caps TD
Cee-vite
Cegiolan
Ceglion
Ceklin
Celaskon
Celin
Cell C
Cemagyl
Ce-mi-lin
Cemill
Cenetone
Cenolate
Cereon
Cergona
Cescorbat
Cetamid
Cetane
Cetane-caps TC
Cetane-caps TD
Cetebe
Cetemican
Cevalin
Cevatine
Cevex
Cevi-bid
Cevimin
Ce-vi-sol
Cevital
Cevitamate
Cevitamic acid
Cevitamin
Cevitan
Cevitex
Cewin
Chewcee
|
Ciamin
Cipca
Citriscorb
Citrovit
C-Level
C-Long
Colascor
Concemin
C-Quin
C-Span
C-Vimin
Davitamon C
Di-L-ascorbate, magnesium
Dora-C-500
Duoscorb
e 300
e300
e-300
Ferrous ascorbate
gamma-Lactone L-threo-hex-2-enonate
gamma-Lactone L-threo-hex-2-enonic acid
HiCee
Hybrin
ido-C
Juvamine
Kangbingfeng
Kyselina askorbova
L Ascorbic acid
L(+)-Ascorbate
L-(+)-Ascorbate
L(+)-Ascorbic acid
L-(+)-Ascorbic acid
L-3-Ketothreohexuronic acid lactone
Laroscorbine
L-Ascorbate
L-Ascorbic acid
Lemascorb
Liqui-cee
L-Lyxoascorbate
L-Lyxoascorbic acid
L-threo-Ascorbic acid
L-Xyloascorbate
L-Xyloascorbic acid
Magnesium ascorbate
Magnesium ascorbicum
Magnesium di L ascorbate
Magnesium di-L-ascorbate
Magnorbin
Meri-c
Monodehydroascorbate radical
Monodehydroascorbic acid radical
Natrascorb
Natrascorb injectable
Planavit C
Proscorbin
Redoxon
Ribena
Ronotec 100
Rontex 100
Roscorbic
Rovimix C
Scorbacid
Scorbu C
Scorbu-C
Secorbate
Semidehydroascorbate
Semidehydroascorbic acid
Sodascorbate
Sodium ascorbate
Suncoat VC 40
Testascorbic
VASC
Vicelat
Vicin
Vicomin C
Viforcit
Viscorin
Viscorin 100m
Vitace
Vitacee
Vitacimin
Vitacin
Vitamin C
Vitamina C
Vitamisin
Vitascorbol
Xitix
|
|
36 |
|
Immunoglobulins |
|
|
|
|
|
37 |
|
Antibodies |
|
|
|
|
|
38 |
|
Vitamins |
|
|
|
|
|
39 |
|
Trace Elements |
|
|
|
|
|
40 |
|
Antioxidants |
|
|
|
|
|
41 |
|
Micronutrients |
|
|
|
|
|
42 |
|
Protective Agents |
|
|
|
|
|
43 |
|
Anesthetics |
|
|
|
|
|
Interventional clinical trials:
(show top 50)
(show all 57)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study |
Recruiting |
NCT02781922 |
Phase 3 |
|
2 |
Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS) |
Completed |
NCT03525418 |
Phase 1, Phase 2 |
|
3 |
Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients |
Completed |
NCT02080637 |
Phase 2 |
Ambrisentan |
4 |
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery |
Completed |
NCT00513240 |
Phase 1, Phase 2 |
Erythropoetin;Normal saline |
5 |
The Sildenafil After Fontan Operation Study |
Completed |
NCT00507819 |
Phase 2 |
Sildenafil;Placebo |
6 |
Treatment With Endothelin Antagonist to Tcpc Patients; a Multicenter, Randomized, Prospective Study Measuring Maximal O2 Uptake in Ergometer Bicycle Test |
Completed |
NCT01292551 |
Phase 2 |
Bosentan;Placebo |
7 |
Phase 2 Study of Intracoronary Infusion of Cardiac Progenitor Cells in Patients With Univentricular Heart Disease |
Completed |
NCT01829750 |
Phase 2 |
|
8 |
Use of Oxandrolone to Promote Growth in Infants With Hypoplastic Left Heart Syndrome: A Phase I/II Pilot Study |
Recruiting |
NCT04090697 |
Phase 1, Phase 2 |
Oxandrolone |
9 |
Evaluation of Lomecel-Bâ„¢ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. |
Recruiting |
NCT04925024 |
Phase 2 |
|
10 |
Prospective, Open-labeled, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of the Second-generation Tissue Engineered Vascular Graft as Vascular Conduits for Extracardiac Total Cavopulmonary Connection. |
Recruiting |
NCT04467671 |
Phase 2 |
|
11 |
Maternal Hyperoxygenation in Congenital Heart Disease |
Recruiting |
NCT03136835 |
Phase 1, Phase 2 |
Maternal Hyperoxygenation |
12 |
Phase IIb Study of Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Stage II Surgical Repair of Right Ventricular Dependent Variants of Hypoplastic Left Heart Syndrome (AutoCell-S2) |
Active, not recruiting |
NCT03779711 |
Phase 2 |
|
13 |
Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle |
Active, not recruiting |
NCT03079401 |
Phase 1, Phase 2 |
|
14 |
Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome |
Completed |
NCT01883076 |
Phase 1 |
|
15 |
Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation |
Completed |
NCT03431480 |
Phase 1 |
|
16 |
Phase I Study of Cardiac Progenitor Cell Therapy in Patients With Single Ventricle Physiology |
Completed |
NCT01273857 |
Phase 1 |
|
17 |
The Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Neonates Following Open Heart Surgery |
Completed |
NCT00576381 |
Phase 1 |
Dexmedetomidine |
18 |
The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery |
Completed |
NCT00573066 |
Phase 1 |
Dexmedetomidine |
19 |
Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. |
Recruiting |
NCT03406884 |
Phase 1 |
|
20 |
The Cold Heart Study: A Randomized Pilot Trial of Surfactant Therapy Following Deep Hypothermic Circulatory Arrest During Cardiac Surgery |
Recruiting |
NCT04181255 |
Phase 1 |
Curosurf;Sham |
21 |
Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study. |
Terminated |
NCT02398604 |
Phase 1 |
Allo-hMSCs;Placebo |
22 |
Autologous Cord Blood Cells for Patients With HLHS: Phase I Study of Feasibility and Safety |
Terminated |
NCT01445041 |
Phase 1 |
|
23 |
Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome-Correlation With Cerebral Non-invasive Infrared Spectroscopy (NIRS) |
Completed |
NCT00399555 |
|
|
24 |
Comparison of Feeding Strategies After Stage 1 Procedures for Hypoplastic Left Heart Syndrome Infants: A Randomized Controlled Trial |
Completed |
NCT02657629 |
|
|
25 |
Family Stress, Coping and Outcomes Following the Diagnosis of Hypoplastic Left Heart Syndrome in a Newborn |
Completed |
NCT00734643 |
|
|
26 |
Neurodevelopmental Outcomes and Postoperative Hemodynamics in Children With Hypoplastic Left Heart Syndrome |
Completed |
NCT00464100 |
|
|
27 |
A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation |
Completed |
NCT01708863 |
|
|
28 |
Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome |
Completed |
NCT01135485 |
|
|
29 |
The Impact of Family Factors on Developmental and Psychosocial Outcomes in Children With Hypoplastic Left Heart Syndrome (HLHS) at 6 Years of Age - Pediatric Heart Network Single Ventricle Reconstruction Extension (SVR II) Ancillary Study |
Completed |
NCT01582529 |
|
|
30 |
Interstitial Colloid Osmotic Pressure in Children With Congenital Heart Defect Preparing for Fontan Surgery Undergoing Preoperative Catheterization and Surgery in General Anesthesia |
Completed |
NCT02306057 |
|
|
31 |
Vitamin C May Improve Endothelial Function and Exercise Capacity in Functional Single Ventricle Patients After Fontan Palliation |
Completed |
NCT00974025 |
|
|
32 |
Randomized Controlled Trial on Deep Hypothermic Circulatory Arrest Versus Antegrade Cerebral Perfusion During Neonatal Cardiac Surgery |
Completed |
NCT01032876 |
|
|
33 |
The GECHO Trial: Genetic Determinants of Congenital Heart Disease Outcomes |
Completed |
NCT01656941 |
|
|
34 |
Physical Activity Promotion in Children and Adolescents With Single Ventricle Physiology (MedBike) |
Completed |
NCT04056416 |
|
|
35 |
Identification of Biomarkers for Heart Failure in Children With Single Ventricle Physiology |
Completed |
NCT00571233 |
|
|
36 |
The Examination of Outcome in Children With Single Ventricle Physiology |
Completed |
NCT00308217 |
|
|
37 |
Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology Requiring Neonatal Surgery |
Completed |
NCT02462434 |
|
|
38 |
Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study) |
Completed |
NCT02184169 |
|
|
39 |
Prophylactic Peritoneal Dialysis Decreases Time to Achieve a Negative Fluid Balance After the Norwood Procedure |
Completed |
NCT01215240 |
|
|
40 |
Cardiac Biomarkers in Patients With Single Ventricle Physiology |
Completed |
NCT03678909 |
|
|
41 |
Near Infrared Spectroscopy Monitoring of Cerebral Oxygen Saturation in Neonatal Cardiac Surgery - Comparison With Common Methods of Estimating Adequate Systemic Perfusion |
Completed |
NCT00166101 |
|
|
42 |
Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease |
Recruiting |
NCT04581668 |
|
|
43 |
Umbilical Cord Blood Collection and Processing for Severe Congenital Heart Disease |
Recruiting |
NCT01856049 |
|
|
44 |
Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease |
Recruiting |
NCT03147014 |
|
|
45 |
Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period (T-NOX) |
Recruiting |
NCT04452188 |
|
|
46 |
Effect of Fetal Aortic Valvuloplasty on Outcomes. A Prospective Observational Cohort Study With a Comparison Cohort |
Recruiting |
NCT05386173 |
|
|
47 |
National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children With Complex Congenital Heart Disease |
Recruiting |
NCT02852031 |
|
|
48 |
Do Cerebral and Renal Saturations Measured With Near-infrared Spectroscopy Correlate With Echocardiographic Markers of Perfusion and Cardiac Performance in Congenital Heart Disease? |
Recruiting |
NCT04106479 |
|
|
49 |
Long-term Outcomes of Children With HLHS (Hypoplastic Left Heart Syndrome) and the Impact of Norwood Shunt Type (A Study Conducted by the Pediatric Heart Network) |
Active, not recruiting |
NCT02455531 |
|
|
50 |
Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome |
Active, not recruiting |
NCT01736956 |
|
|
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Hypoplastic Left Heart Syndrome:
Embryonic/Adult Cultured Cells Related to Hypoplastic Left Heart Syndrome:
|